Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background The spread of tau pathology closely correlates with the disease course and cognitive decline in Alzheimer's disease (AD). Tau-targeting immunotherapies are being developed to stop the spread of tau pathology and thus halt disease progression. In this post hoc analysis of the ADAMANT clinical trial, we examined the performance of AADvac1, an active immunotherapy targeting the microtubule-binding region (MTBR) of tau, in a subgroup of participants with elevated plasma p-tau217, indicating AD-related neuropathological changes. Methods ADAMANT was a 24-month, randomized, placebo-controlled, parallel-group, double-blinded, multicenter, phase 2 clinical trial in subjects with mild AD. The trial participants were randomized 3:2 to receive six doses of AADvac1 or placebo at 4-week intervals, followed by five booster doses at 14-week intervals. The primary outcome was safety. The secondary outcomes were the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Cooperative Study - Activities of Daily Living score for Mild Cognitive Impairment 18-item version (ADCS-ADL-MCI-18), and immunogenicity. Volumetric MRI, plasma neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) were exploratory outcomes. The inclusion criterion for this post-hoc analysis was a baseline plasma p-tau217 level above the cutoff for AD. Results Among 196 ADAMANT participants, 137 were positive for plasma p-tau217 (mean age 71.4 years, 59% women). AADvac1 was safe and well tolerated in this subgroup. AADvac1 reduced the rate of accumulation of log-plasma NfL by 56% and that of GFAP by 73%. The treatment differences in the CDR-SB and ADCS-ADL-MCI-18 scores favored AADvac1 but were not statistically significant. AADvac1 had no effect on whole-brain volume but nonsignificantly reduced the loss of brain cortical tissue in several regions. Importantly, the impact on the study outcomes was more pronounced in participants with higher anti-tau antibody levels. Conclusions These results suggest that AADvac1 tau immunotherapy can reduce plasma biomarkers of neurodegeneration and neuroinflammation. These findings and possible observations on brain atrophy and cognition are hypothesis-generating and warrant further evaluation in a larger clinical trial. Trial registration EudraCT 2015-000630-30 (primary) and NCT02579252.

What this study adds

Evidence grade: High

In a later look at the ADAMANT trial, 137 of 196 participants with mild Alzheimer's had high blood p-tau217, and in this group the tau vaccine AADvac1 was safe and well tolerated. It reduced the build-up of the blood markers NfL by 56% and GFAP by 73%, but its edge on thinking and daily-living scores was not statistically significant.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kovacech, B., Cullen, N. C., Novak, P., Hanes, J., Kontsekova, E., Katina, S., et al. (2024). Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-024-01620-7

Vancouver

Kovacech B, Cullen NC, Novak P, Hanes J, Kontsekova E, Katina S, et al. Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217. Alzheimer's research & therapy. 2024. doi:10.1186/s13195-024-01620-7. PMID: 39580468.

BibTeX

@article{kovacech2024-39580468,
  author  = {Kovacech, B. and Cullen, N. C. and Novak, P. and Hanes, J. and Kontsekova, E. and Katina, S. and Parrak, V. and Fresser, M. and others},
  title   = {{Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01620-7},
  pmid    = {39580468},
  url     = {https://doi.org/10.1186/s13195-024-01620-7}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In a later look at the ADAMANT trial, 137 of 196 participants with mild Alzheimer's had high blood p-tau217, and in this group the tau vaccine AADvac1 was safe and well tolerated. It reduced the build-up of the blood markers NfL by 56% and GFAP by 73%, but its edge on thinking and daily-living scores was not statistically significant. The authors call these results hypothesis-generating and say a larger trial is needed.

Study details

How this study scored 65/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 65 of 100.65 of 100 points earned35 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer's research & therapy)
Journal's citation record 1 / 4 Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 3 / 7 Cited 20 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.0 citations a year over 4 year(s) since 2024
Impact for its field and year 3 / 6 Cited 4.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Norbert Žilka: h-index 39 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California San Diego: institution h-index 1,852 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39580468)
Free to read 2 / 2 Free to read
Total 65 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Inflammation and the immune system from nearby years

Also tagged “phosphorylated”

733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →